Harper says that Amgen is aware of the mediocre results for IGF1 drugs elsewhere, but decided to go ahead in pancreatic cancer because of strong results it got in second stage trials, where its drug delayed the progression of the disease by about four months.
The second is The Diabetes Prevention Program, which has illustrated that it is indeed possible to prevent the progression of pre-diabetes to diabetes.
The second thing that we learned is that we were not able to show an impact on time to disease progression in the way that we measured it, which was the time to the next progression event or two lesions in the bone.